IPO Benefits And Challenges For Early-Stage Biotech Cos.

Law360 (December 4, 2019, 5:02 PM EST) -- Initial public offerings have become an increasingly popular way for early-stage biotech companies, including companies in preclinical development and companies conducting phase-one clinical trials, to raise capital and position themselves to successfully execute their development plans and elevate their profiles.

There were over 60 biotech IPOs in 2018 alone and the trend continues in 2019, although it is a bit more volatile. An early-stage biotech company’s significant capital needs and growth potential, coupled with the expanding demand for interesting and innovative drugs, technology and health care solutions, make the IPO an attractive alternative to private investment for capital infusion and market...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS